Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

Study title: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study Publication ...

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as ...

AVEO Oncology, an LG Chem company ("AVEO"), announced today that the TiNivo-2 Phase 3 clinical trial results in patients with ...

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic ...

Study title: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study Publication: The ...

Tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has antiangiogenic effects and is thought to be synergistic with an ICI. Eligible patients had received one or ...